Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-α2b fusion protein expressed in Pichia pastoris

被引:46
作者
Huang, Yan-Shan
Chen, Zhi
Yang, Zhi-Yu
Wang, Tong-Ying
Zhou, Li [1 ]
Wu, Jian-Binr
Zhou, Lin-Fu [1 ]
机构
[1] Zhejiang Univ, Fac Basic Med, Inst Med Biotechnol, Sch Med, Hangzhou 310005, Peoples R China
[2] Zhejiang Univ, Inst Infect Dis, Hangzhou 310027, Peoples R China
[3] Hangzhou Jiuyuan Gene Engn Co Ltd, Zhejiang, Peoples R China
关键词
bioactivity; characterization; peptide mapping; Pichia pastoris; purification; recombinant human serum albumin-interferon-alpha 2b;
D O I
10.1016/j.ejpb.2007.02.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A long-lasting recombinant human serum albumin-interferon-alpha 2b fusion protein (rHSA/IFN alpha 2b) was prepared and its structure and biological activities were studied. rHSA/IFN alpha 2b was expressed in methylotrophic yeast Pichia pastoris with HSA's natural signal peptide and purified by dye affinity chromatography, hydrophobic interaction chromatography, ion exchange chromatography and Sephadex G25. Purity of the prepared rHSA/IFN alpha 2b was greater than 97% analyzed by non-reduced SDS-PAGE and RP-HPLC. Structure and biological activities of the prepared rHSA/IFN alpha 2b were characterized by physical, chemical and biological methods. Its pI was 5.3 and showed a single band on IEF gel. Molecular weight determined by MALDI-TOF was 86004.3 +/- 29.2. Amino-terminal and carboxyl-terminal amino acid sequences were identical to predicted sequence. Its specific activity in vitro was 6.3 +/- 0.8 x 10(5) IU/mg fusion protein, retaining about 1.4% of that of unmodified rIFN alpha on a molar basis. After administered in monkeys, significant increases of 2',5'-oligoadenylate synthetase activity relative to IFN-alpha were maintained for 14 days in serum and the rHSA/IFN alpha 2b showed more potent biological activity than IFN-alpha on a molar basis. Therefore, markedly improved in vivo biological activity of rHSA/IFN alpha 2b could exhibit more potent antiviral activity than IFN alpha 2b in future clinical trials. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 308
页数:8
相关论文
共 22 条
[1]   Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[2]   Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein [J].
Bowen, S ;
Tare, N ;
Inoue, T ;
Yamasaki, M ;
Okabe, M ;
Horii, I ;
Eliason, JF .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (03) :425-432
[3]   Heterologous protein expression in the methylotrophic yeast Pichia pastoris [J].
Cereghino, JL ;
Cregg, JM .
FEMS MICROBIOLOGY REVIEWS, 2000, 24 (01) :45-66
[4]   Expression of heterologous proteins in Pichia pastoris:: a useful experimental tool in protein engineering and production [J].
Daly, R ;
Hearn, MTW .
JOURNAL OF MOLECULAR RECOGNITION, 2005, 18 (02) :119-138
[5]   A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon [J].
Fattovich, G ;
Giustina, G ;
Favarato, S ;
Ruol, A ;
Macarri, G ;
Orlandi, F ;
Iaquinto, G ;
Ambrosone, L ;
Francavilla, A ;
Pastore, G ;
Santantonio, MT ;
Romagno, D ;
Bolondi, L ;
Sofia, S ;
Marchesini, A ;
Pisi, E ;
Mazzella, G ;
Roda, E ;
Attaro, L ;
Chiodo, F ;
Mori, F ;
Verucchi, G ;
Lanzini, A ;
Salmi, A ;
Calvi, B ;
Bozzetti, F ;
Radaeli, E ;
Bernasconi, M ;
Pilleri, G ;
Bacca, D ;
Romano, G ;
Mastrapasqua, G ;
Cozzolongo, R ;
Cacopardo, B ;
Nunnari, A ;
Blasi, A ;
Sala, LO ;
Minoli, G ;
Sangiovanni, A ;
Spinzi, GC ;
Colombo, A ;
Camassa, M ;
Riva, D ;
Maggi, G ;
Boccia, S ;
Gualandi, G ;
Nucci, A ;
Pacini, F ;
Marino, N ;
Mazzotta, F .
JOURNAL OF HEPATOLOGY, 1996, 24 (01) :38-47
[6]   Interferons in host defense [J].
Foster, GR .
SEMINARS IN LIVER DISEASE, 1997, 17 (04) :287-295
[7]   Pegylated interferon-α2b:: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data [J].
Glue, P ;
Fang, JWS ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :556-567
[8]  
HIGGING DR, 1998, METHODS MOL BIOL PIC
[9]  
HODGKINS MA, 1990, YEAST, V65, P435
[10]   Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection [J].
Hu, KQ ;
Vierling, JM ;
Redeker, AG .
JOURNAL OF VIRAL HEPATITIS, 2001, 8 (01) :1-18